Rheumatic disease patients show low response to COVID-19 booster
Study finds on average they display half the cross-neutralising response to Omicron as healthy controls
Three doses of COVID-19 vaccine fail to provide sufficient protection against the Omicron variant in patients with autoimmune rheumatic diseases, an observational study shows.
Korean researchers say the “exceptionally weak” immune response to the dominant SARS-CoV-2 strain seen in this at-risk population highlights their vulnerability to breakthrough infections.
Their findings are based on analyses of blood samples from 149 patients with rheumatoid arthritis, SLE and other autoimmune conditions,
